文献速递心血管MR

心脏MRI可显示免疫检查点抑制剂诱导的心肌炎:一项前瞻性研究

Cardiac MRI Depicts Immune Checkpoint Inhibitor-induced Myocarditis: A Prospective Study.
PubMed 文献 · Radiology · 2021-09-28

这项前瞻性研究对22例接受免疫检查点抑制剂(ICI)治疗的肿瘤患者,在基线和治疗后3个月进行多参数心脏MRI检查。结果显示随访时心肌水肿标志物(T1、T2弛豫时间及T2信号强度比)较基线显著升高,左心室平均收缩期纵向应变减低,新发非缺血性LGE见于2/22例(9%),小量心包积液更常见(从1/22例增至10/22例)。结论认为心脏MRI可检测到ICI治疗相关的心肌水肿、炎症和收缩功能异常。

要点

  • ICI治疗后3个月心脏MRI可见T1、T2弛豫时间及T2信号强度比升高,提示弥漫性心肌水肿。
  • 左心室平均收缩期纵向应变从基线-23.4%降至-19.6%,提示收缩功能亚临床减退。
  • 新发非缺血性LGE仅见于2/22例(9%),小量心包积液在随访时更常见(10/22例,45%)。

关键影像表现/征象

  • 随访时T1弛豫时间较基线升高(972 msec ± 26 vs 1006 msec ± 36,P < .001),提示弥漫性心肌水肿。
  • 随访时T2弛豫时间较基线升高(54 msec ± 3 vs 58 msec ± 4,P < .001),T2信号强度比亦升高(1.5 ± 0.3 vs 1.7 ± 0.3,P = .03)。
  • 左心室平均收缩期纵向应变在随访时减低(-23.4% ± 4.8 vs -19.6% ± 5.1,P = .005)。
  • 新发非缺血性LGE见于2/22例参与者(9%)。
  • 小量心包积液在随访时更明显(基线1/22例[5%] vs 随访10/22例[45%],P = .004)。

临床应用与阅片要点

  • 对接受ICI治疗且无心脏症状的患者,心脏MRI多参数序列(T1、T2 mapping、应变、LGE)有助于检出亚临床心肌水肿和收缩功能异常。
  • 阅片时需关注T1、T2弛豫时间及T2信号强度比的轻度升高,以及纵向应变减低,这些可能提示ICI相关亚临床心肌损伤。
  • 新发非缺血性LGE和小量心包积液可作为辅助征象,但LGE阳性率较低(9%),阴性不能排除亚临床受累。

局限性

  • 样本量小(22例),未设对照组,结果需更大规模研究验证。
  • 随访时间仅为开始ICI治疗后3个月,缺乏长期随访数据。
  • 研究对象为无已知结构性心脏病或心脏症状的患者,结论不能直接推广至有基础心脏病或症状性心肌炎患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Background Immune checkpoint inhibitors (ICIs) for cancer treatment are associated with a spectrum of immune-related adverse events, including ICI-induced myocarditis; however, the extent of subclinical acute cardiac effects related to ICI treatment is unclear. Purpose To explore the extent of cardiac injury and inflammation related to ICI therapy that can be detected with use of cardiac MRI. Materials and Methods In this prospective study from November 2019 to April 2021, oncologic participants, without known underlying structural heart disease or cardiac symptoms, underwent multiparametric cardiac MRI before planned ICI therapy (baseline) and 3 months after starting ICI therapy (follow-up). The cardiac MRI protocol incorporated assessment of cardiac function, including systolic myocardial strain, myocardial edema, late gadolinium enhancement (LGE), T1 and T2 relaxation times, and extracellular volume fraction. The paired t test, Wilcoxon signed-rank test, and McNemar test were used for intraindividual comparisons. Results Twenty-two participants (mean age ± standard deviation, 65 years ± 14; 13 men) were evaluated, receiving a median of four infusions of ICI therapy (interquartile range, four to six infusions). Compared with baseline MRI, participants displayed increased markers of diffuse myocardial edema at follow-up (T1 relaxation time, 972 msec ± 26 vs 1006 msec ± 36 [P < .001]; T2 relaxation time, 54 msec ± 3 vs 58 msec ± 4 [P < .001]; T2 signal intensity ratio, 1.5 ± 0.3 vs 1.7 ± 0.3 [P = .03]). Left ventricular average systolic longitudinal strain had decreased at follow-up MRI (-23.4% ± 4.8 vs -19.6% ± 5.1, respectively; P = .005). New nonischemic LGE lesions were prevalent in two of 22 participants (9%). Compared with baseline, small pericardial effusions were more evident at follow-up (one of 22 participants [5%] vs 10 of 22 [45%]; P = .004). Conclusion In participants who received immune checkpoint inhibitor therapy for cancer treatment, follow-up cardiac MRI scans showed signs of systolic dysfunction and increased parameters of myocardial edema and inflammation. © RSNA, 2021 Online supplemental material is available for this article.

来源:Radiology,查看原文。版权归原作者所有。

引用

  1. Faron A, Isaak A, Mesropyan N, et al. Cardiac MRI Depicts Immune Checkpoint Inhibitor-induced Myocarditis: A Prospective Study. Radiology. 2021. PMID: 34581628. doi:10.1148/radiol.2021210814

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。